Rubella vaccine in the People's Republic of China.
The results of seroepidemiologic surveys indicate that rubella is widely prevalent in China. Congenital rubella infection has posed a threat. To control rubella and decrease the incidence of congenital rubella infection, an attenuated strain of rubella virus was developed in China. The original strain was isolated from a throat-swab specimen from a six-year-old girl with a clinical diagnosis of rubella. The strain was passaged and attenuated in human diploid cells and named BRD-2. The results of clinical trials showed that the BRD-2 virus strain has mild reactogenicity, satisfactory immunogenicity, and no transmissibility. The antigenicity and reactogenicity are comparable to those of strain RA27/3. It is anticipated that it may be put into production in the near future.
D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis; D002648:Child; D002675:Child, Preschool; D002681:China; D005260:Female; D006801:Humans; D012411:Rubella Vaccine / Q000009:adverse effects / Q000276:immunology*; D012412:Rubella virus / Q000276:immunology; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000276:immunology
D000914:Antibodies, Viral; D012411:Rubella Vaccine; D014613:Vaccines, Attenuated